Clinical trials / NCT03340675
NCT03340675Phase 2Completed

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

Study sponsor: Cumberland Pharmaceuticals

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2024-03-06Actual
Enrollment · participants46Actual
Source updated2026-03-17Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Recruitment status changed

− Before

Active not recruiting

+ After

Completed

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Incidence of Treatment-Emergent Adverse Events (Safety & Tolerability)

+ After

Measure: Incidence of Treatment-Emergent Adverse Events

Check registry source

· 5 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Incidence of Treatment-Emergent Adverse Events (safety & tolerability)

+ After

Measure: Incidence of Treatment-Emergent Adverse Events (Safety & Tolerability)

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

48 participants (planned)

+ After

46 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

Sep 2025

+ After

6 Mar 2024

Check registry source